News

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

GE HealthCare

The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.” 

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Hexoskin Medical System

According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. 

 Emily Sedgwick, MD, MBA

The breast screening provider has picked Emily Sedgwick, MD, MBA, to fill the key role and is opening new centers in Texas and Colorado. 

allstate

Filed in a Texas federal court, the complaint names Prime Imaging Partners and Memorial MRI & Diagnostic among numerous defendants, with the alleged auto-injury scheme occurring from 2019-2023. 

piedmont

The private equity-backed, Tennessee-based imaging group is expanding in Georgia and Missouri through partnerships with Piedmont and BJC HealthCare, respectively. 

lung cancer screening

By giving providers greater insight into a tumor’s molecular footprint, the method could also reduce the need for invasive biopsies.

pediatric pacemaker

A team of pediatric specialists worked closely with representative from Medtronic to develop the new pacemakers. Overall, the tiny devices—approximately one-quarter the size of a traditional pacemaker—were found to be both safe and effective. They are still under development.

These findings may lead to new screening guidelines that could change how imaging is utilized in the aging population.

primary care provider clinician physician doctor

Nominees for the Cardiovascular Business Forty Under 40 Awards can now be submitted through Sunday, March 9.

Around the web

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.” 

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.